Results 91 to 100 of about 480,865 (305)
Molecular Oncology, EarlyView.Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer [PDF]
, 2012 Epidermal growth factor receptor (EGFR) mutations are predictive of response to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Several methods have been used to detect EGFR mutations; however, it is not clear which is the most suitable for use in the ...
Tomonaga, Nanae +11 more
core +1 more source
Spatial biology in cancer epigenetics
Molecular Oncology, EarlyView.Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley +1 more source
The value of patient-reported outcomes in lung cancer clinical trials
JTCVS Open, 2022 Cecilia Pompili, MD, PhD, Jill Feldman
doaj +1 more source
Molecular Oncology, EarlyView.This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi +6 more
wiley +1 more source
Nanomaterials, 2019 Intraoperative definition of tumor free resection margins in head and neck cancer is challenging. In the current proof-of-principle study we evaluated a novel silica nanoparticle-based agent for its potential use as contrast enhancer.
Anna Watermann +7 more
doaj +1 more source
Experimental Cell Research, 2011 Anti-Epidermal Growth Factor Receptor (EGFR) therapies have been recently developed for the treatment of multiple cancer types. At the time when they were introduced in clinical practice, there was little knowledge of the molecular bases of tumor sensitivity and resistance to these novel targeted compounds.
Vecchione L +4 more
openaire +4 more sources
Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk
Molecular Oncology, EarlyView.Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley +1 more source
, 2018 Miaomiao Wen,1 Jinghua Xia,1 Ying Sun,1 Xuejiao Wang,1 Xianghui Fu,2 Yanning Zhang,1 Zhipei Zhang,1 Yongan Zhou,1 Xiaofei Li1 1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an 710038, Shaanxi, China ...
Li X +8 more
core
Development of a novel EGFR-targeted peptide for targeted delivery of drugs in anaplastic thyroid cancer [PDF]
, 2023 peer reviewedAnaplastic thyroid carcinoma (ATC) represents the most aggressive and deadliest thyroid cancer in human with a high proliferative and metastatic potential. The median survival of patients with ATC is of about 4 months after diagnosis and the
Journe, Fabrice +7 more
core